Luis E Simental-Mendía, Mario Simental-Mendía, Claudia I Gamboa-Gómez, Tannaz Jamialahmadi, Amirhossein Sahebkar
{"title":"贝特类药物对脂蛋白相关磷脂酶A2质量和活性的影响：对照临床试验的系统回顾和荟萃分析","authors":"Luis E Simental-Mendía, Mario Simental-Mendía, Claudia I Gamboa-Gómez, Tannaz Jamialahmadi, Amirhossein Sahebkar","doi":"10.2174/0113816128345231240925095400","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In vascular tissue, macrophages and inflammatory cells produce the enzyme lipoprotein- associated phospholipase A2 (Lp-PLA2). Treatment with fibrates decreases Lp-PLA2 levels in individuals with obesity and metabolic syndrome; however, these findings have not been fully clarified.</p><p><strong>Objective: </strong>The goal of this study was to investigate the possible effects of fibrate therapy on Lp-PLA2 mass and activity through a meta-analysis of clinical trials.</p><p><strong>Methods: </strong>Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched using MeSH terms and keywords. Randomized controlled trials (RCT) evaluating the effect of statins on Lp- PLA2 mass and/or activity were included in the meta-analysis. Quantitative data were analyzed using a random- effects model and the generic inverse variance method.</p><p><strong>Results: </strong>The meta-analysis of 10 clinical trials indicated that fibrate treatment has no significant effect on Lp- PLA2 mass (fibrate vs. placebo/nothing = WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, p = 0.72; fibrate vs. active control = WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, p = 0.97); Lp-PLA2 activity (fibrate vs. active control = WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, p = 0.10); HDL-LpPLA2 activity (fibrate vs. active control = WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, p = 0.17); and secretory PLA2 (fibrate vs. active control = WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, p = 0.65). Also, the results of the sensitivity analysis were robust for all these parameters.</p><p><strong>Conclusion: </strong>In conclusion, fibrate therapy did not reduce the mass and activity of Lp-PLA2.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials.\",\"authors\":\"Luis E Simental-Mendía, Mario Simental-Mendía, Claudia I Gamboa-Gómez, Tannaz Jamialahmadi, Amirhossein Sahebkar\",\"doi\":\"10.2174/0113816128345231240925095400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In vascular tissue, macrophages and inflammatory cells produce the enzyme lipoprotein- associated phospholipase A2 (Lp-PLA2). Treatment with fibrates decreases Lp-PLA2 levels in individuals with obesity and metabolic syndrome; however, these findings have not been fully clarified.</p><p><strong>Objective: </strong>The goal of this study was to investigate the possible effects of fibrate therapy on Lp-PLA2 mass and activity through a meta-analysis of clinical trials.</p><p><strong>Methods: </strong>Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched using MeSH terms and keywords. Randomized controlled trials (RCT) evaluating the effect of statins on Lp- PLA2 mass and/or activity were included in the meta-analysis. Quantitative data were analyzed using a random- effects model and the generic inverse variance method.</p><p><strong>Results: </strong>The meta-analysis of 10 clinical trials indicated that fibrate treatment has no significant effect on Lp- PLA2 mass (fibrate vs. placebo/nothing = WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, p = 0.72; fibrate vs. active control = WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, p = 0.97); Lp-PLA2 activity (fibrate vs. active control = WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, p = 0.10); HDL-LpPLA2 activity (fibrate vs. active control = WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, p = 0.17); and secretory PLA2 (fibrate vs. active control = WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, p = 0.65). Also, the results of the sensitivity analysis were robust for all these parameters.</p><p><strong>Conclusion: </strong>In conclusion, fibrate therapy did not reduce the mass and activity of Lp-PLA2.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128345231240925095400\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128345231240925095400","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景：在血管组织中，巨噬细胞和炎症细胞产生脂蛋白相关磷脂酶A2 （Lp-PLA2）。贝特类药物治疗可降低肥胖和代谢综合征患者的Lp-PLA2水平；然而，这些发现尚未得到充分澄清。目的：本研究的目的是通过临床试验的荟萃分析，探讨贝特治疗对Lp-PLA2质量和活性的可能影响。方法：使用MeSH术语和关键词检索Web of Science、PubMed、Scopus、谷歌Scholar和ClinicalTrials.gov数据库。meta分析纳入了评估他汀类药物对Lp- PLA2质量和/或活性影响的随机对照试验（RCT）。定量数据采用随机效应模型和通用逆方差法进行分析。结果：10项临床试验的荟萃分析显示，贝特治疗对Lp- PLA2质量无显著影响(贝特与安慰剂/无治疗= WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, p = 0.72；贝特与主动对照= WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, p = 0.97)；Lp-PLA2活性（贝特与主动对照= WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, p = 0.10）；HDL-LpPLA2活性（纤维对照与主动对照= WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, p = 0.17）；分泌PLA2（贝特与主动对照= WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, p = 0.65）。此外，敏感性分析的结果对所有这些参数都是稳健的。结论：贝特治疗未降低Lp-PLA2的质量和活性。
Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials.
Background: In vascular tissue, macrophages and inflammatory cells produce the enzyme lipoprotein- associated phospholipase A2 (Lp-PLA2). Treatment with fibrates decreases Lp-PLA2 levels in individuals with obesity and metabolic syndrome; however, these findings have not been fully clarified.
Objective: The goal of this study was to investigate the possible effects of fibrate therapy on Lp-PLA2 mass and activity through a meta-analysis of clinical trials.
Methods: Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched using MeSH terms and keywords. Randomized controlled trials (RCT) evaluating the effect of statins on Lp- PLA2 mass and/or activity were included in the meta-analysis. Quantitative data were analyzed using a random- effects model and the generic inverse variance method.
Results: The meta-analysis of 10 clinical trials indicated that fibrate treatment has no significant effect on Lp- PLA2 mass (fibrate vs. placebo/nothing = WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, p = 0.72; fibrate vs. active control = WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, p = 0.97); Lp-PLA2 activity (fibrate vs. active control = WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, p = 0.10); HDL-LpPLA2 activity (fibrate vs. active control = WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, p = 0.17); and secretory PLA2 (fibrate vs. active control = WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, p = 0.65). Also, the results of the sensitivity analysis were robust for all these parameters.
Conclusion: In conclusion, fibrate therapy did not reduce the mass and activity of Lp-PLA2.
期刊介绍：
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
